The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-06-07

AUTHORS

Ying Cai, Wenli Cui, Weixiang Chen, Ping Wei, Yayun Chi, Ping Zhang, Rui Bi, Xiaoyan Zhou

ABSTRACT

BACKGROUND: Epigenetic control using histone deacetylase (HDAC) inhibitors is a promising therapy for lymphomas. Insights into the anti-proliferative effects of HDAC inhibitors on diffuse large B-cell lymphoma (DLBCL) and further understanding of the underlying mechanisms, which remain unclear to date, are of great importance. METHODS: Three DLBCL cell lines (DoHH2, LY1 and LY8) were used to define the potential epigenetic targets for Trichostatin A (TSA)-mediated anti-proliferative effects via CCK-8 assay. Cell cycle distribution and apoptosis were detected by flow cytometry. We further investigated the underlying molecular mechanisms by examining expression levels of relevant proteins using western blot analysis. RESULTS: TSA treatment inhibited the growth of all three DLBCL cell lines and enhanced cell cycle arrest and apoptosis. Molecular analysis revealed upregulated acetylation of histone H3, α-tubulin and p53, and dephosphorylation of pAkt with altered expression of its main downstream effectors (p21, p27, cyclin D1 and Bcl-2). HDAC profiling revealed that all three cell lines had varying HDAC1-6 expression levels, with the highest expression of all six isoforms, in DoHH2 cells, which displayed the highest sensitivity to TSA. CONCLUSION: Our results demonstrated that the HDAC inhibitor TSA inhibited DLBCL cell growth, and that cell lines with higher expression of HDACs tended to be more sensitive to TSA. Our data also suggested that inhibition of pAkt and activation of p53 pathway are the main molecular events involved in inhibitory effects of TSA. More... »

PAGES

57-57

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1475-2867-13-57

DOI

http://dx.doi.org/10.1186/1475-2867-13-57

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036997840

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23758695


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Pathology, Fudan University, Shanghai, PR China", 
          "id": "http://www.grid.ac/institutes/grid.8547.e", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China", 
            "Institute of Pathology, Fudan University, Shanghai, PR China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cai", 
        "givenName": "Ying", 
        "id": "sg:person.0667777664.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667777664.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Pathology, Fudan University, Shanghai, PR China", 
          "id": "http://www.grid.ac/institutes/grid.8547.e", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China", 
            "Institute of Pathology, Fudan University, Shanghai, PR China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cui", 
        "givenName": "Wenli", 
        "id": "sg:person.01336110623.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336110623.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Pathology, Fudan University, Shanghai, PR China", 
          "id": "http://www.grid.ac/institutes/grid.8547.e", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China", 
            "Institute of Pathology, Fudan University, Shanghai, PR China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Weixiang", 
        "id": "sg:person.0674362262.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674362262.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Pathology, Fudan University, Shanghai, PR China", 
          "id": "http://www.grid.ac/institutes/grid.8547.e", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China", 
            "Institute of Pathology, Fudan University, Shanghai, PR China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wei", 
        "givenName": "Ping", 
        "id": "sg:person.01257402372.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257402372.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research Institute, Fudan University Shanghai Cancer Center, Shanghai, PR China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China", 
            "Institute of Pathology, Fudan University, Shanghai, PR China", 
            "Cancer Research Institute, Fudan University Shanghai Cancer Center, Shanghai, PR China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "Yayun", 
        "id": "sg:person.01117741622.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117741622.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research Institute, Fudan University Shanghai Cancer Center, Shanghai, PR China", 
          "id": "http://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Cancer Research Institute, Fudan University Shanghai Cancer Center, Shanghai, PR China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Ping", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Pathology, Fudan University, Shanghai, PR China", 
          "id": "http://www.grid.ac/institutes/grid.8547.e", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China", 
            "Institute of Pathology, Fudan University, Shanghai, PR China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bi", 
        "givenName": "Rui", 
        "id": "sg:person.01103220634.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103220634.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Pathology, Fudan University, Shanghai, PR China", 
          "id": "http://www.grid.ac/institutes/grid.8547.e", 
          "name": [
            "Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China", 
            "Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China", 
            "Institute of Pathology, Fudan University, Shanghai, PR China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhou", 
        "givenName": "Xiaoyan", 
        "id": "sg:person.01010610662.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010610662.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6600905", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051493456", 
          "https://doi.org/10.1038/sj.bjc.6600905"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2012.81", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012645003", 
          "https://doi.org/10.1038/onc.2012.81"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1210614", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051261327", 
          "https://doi.org/10.1038/sj.onc.1210614"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-010-9591-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051959658", 
          "https://doi.org/10.1007/s10637-010-9591-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-06-07", 
    "datePublishedReg": "2013-06-07", 
    "description": "BACKGROUND: Epigenetic control using histone deacetylase (HDAC) inhibitors is a promising therapy for lymphomas. Insights into the anti-proliferative effects of HDAC inhibitors on diffuse large B-cell lymphoma (DLBCL) and further understanding of the underlying mechanisms, which remain unclear to date, are of great importance.\nMETHODS: Three DLBCL cell lines (DoHH2, LY1 and LY8) were used to define the potential epigenetic targets for Trichostatin A (TSA)-mediated anti-proliferative effects via CCK-8 assay. Cell cycle distribution and apoptosis were detected by flow cytometry. We further investigated the underlying molecular mechanisms by examining expression levels of relevant proteins using western blot analysis.\nRESULTS: TSA treatment inhibited the growth of all three DLBCL cell lines and enhanced cell cycle arrest and apoptosis. Molecular analysis revealed upregulated acetylation of histone H3, \u03b1-tubulin and p53, and dephosphorylation of pAkt with altered expression of its main downstream effectors (p21, p27, cyclin D1 and Bcl-2). HDAC profiling revealed that all three cell lines had varying HDAC1-6 expression levels, with the highest expression of all six isoforms, in DoHH2 cells, which displayed the highest sensitivity to TSA.\nCONCLUSION: Our results demonstrated that the HDAC inhibitor TSA inhibited DLBCL cell growth, and that cell lines with higher expression of HDACs tended to be more sensitive to TSA. Our data also suggested that inhibition of pAkt and activation of p53 pathway are the main molecular events involved in inhibitory effects of TSA.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1475-2867-13-57", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1030596", 
        "issn": [
          "1475-2867"
        ], 
        "name": "Cancer Cell International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "DLBCL cell lines", 
      "histone deacetylase inhibitors", 
      "cell lines", 
      "potential epigenetic targets", 
      "HDAC inhibitor TSA", 
      "expression levels", 
      "main downstream effectors", 
      "deacetylase inhibitors", 
      "anti-proliferative effects", 
      "enhanced cell cycle arrest", 
      "main molecular events", 
      "DLBCL cell growth", 
      "cell cycle arrest", 
      "epigenetic control", 
      "high expression", 
      "histone H3", 
      "epigenetic targets", 
      "downstream effectors", 
      "cell cycle distribution", 
      "cell lymphoma cell lines", 
      "trichostatin A", 
      "molecular mechanisms", 
      "TSA treatment", 
      "molecular events", 
      "relevant proteins", 
      "Western blot analysis", 
      "lymphoma cell lines", 
      "CCK-8 assay", 
      "cycle arrest", 
      "molecular analysis", 
      "cell growth", 
      "p53 pathway", 
      "altered expression", 
      "HDAC inhibitors", 
      "blot analysis", 
      "inhibition of pAKT", 
      "cycle distribution", 
      "expression", 
      "apoptosis", 
      "DoHH2 cells", 
      "flow cytometry", 
      "inhibitors", 
      "TSA", 
      "pAkt", 
      "further understanding", 
      "dephosphorylation", 
      "H3", 
      "mechanism", 
      "lines", 
      "HDACs", 
      "protein", 
      "growth", 
      "acetylation", 
      "effectors", 
      "isoforms", 
      "tubulin", 
      "biological behavior", 
      "profiling", 
      "inhibitory effect", 
      "pathway", 
      "insights", 
      "p53", 
      "cells", 
      "activation", 
      "assays", 
      "arrest", 
      "promising therapy", 
      "cytometry", 
      "cell lymphoma", 
      "inhibition", 
      "target", 
      "levels", 
      "lymphoma", 
      "great importance", 
      "analysis", 
      "understanding", 
      "effect", 
      "events", 
      "importance", 
      "diffuse", 
      "therapy", 
      "date", 
      "distribution", 
      "treatment", 
      "control", 
      "high sensitivity", 
      "sensitivity", 
      "data", 
      "results", 
      "behavior", 
      "upregulated acetylation", 
      "dephosphorylation of pAkt", 
      "HDAC profiling", 
      "HDAC1-6 expression levels", 
      "inhibitor TSA"
    ], 
    "name": "The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms", 
    "pagination": "57-57", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036997840"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1475-2867-13-57"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23758695"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1475-2867-13-57", 
      "https://app.dimensions.ai/details/publication/pub.1036997840"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_607.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1475-2867-13-57"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1475-2867-13-57'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1475-2867-13-57'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1475-2867-13-57'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1475-2867-13-57'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      22 PREDICATES      125 URIs      113 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1475-2867-13-57 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nb69f5e1f1be542768233eed4e9f105ad
4 schema:citation sg:pub.10.1007/s10637-010-9591-3
5 sg:pub.10.1038/onc.2012.81
6 sg:pub.10.1038/sj.bjc.6600905
7 sg:pub.10.1038/sj.onc.1210614
8 schema:datePublished 2013-06-07
9 schema:datePublishedReg 2013-06-07
10 schema:description BACKGROUND: Epigenetic control using histone deacetylase (HDAC) inhibitors is a promising therapy for lymphomas. Insights into the anti-proliferative effects of HDAC inhibitors on diffuse large B-cell lymphoma (DLBCL) and further understanding of the underlying mechanisms, which remain unclear to date, are of great importance. METHODS: Three DLBCL cell lines (DoHH2, LY1 and LY8) were used to define the potential epigenetic targets for Trichostatin A (TSA)-mediated anti-proliferative effects via CCK-8 assay. Cell cycle distribution and apoptosis were detected by flow cytometry. We further investigated the underlying molecular mechanisms by examining expression levels of relevant proteins using western blot analysis. RESULTS: TSA treatment inhibited the growth of all three DLBCL cell lines and enhanced cell cycle arrest and apoptosis. Molecular analysis revealed upregulated acetylation of histone H3, α-tubulin and p53, and dephosphorylation of pAkt with altered expression of its main downstream effectors (p21, p27, cyclin D1 and Bcl-2). HDAC profiling revealed that all three cell lines had varying HDAC1-6 expression levels, with the highest expression of all six isoforms, in DoHH2 cells, which displayed the highest sensitivity to TSA. CONCLUSION: Our results demonstrated that the HDAC inhibitor TSA inhibited DLBCL cell growth, and that cell lines with higher expression of HDACs tended to be more sensitive to TSA. Our data also suggested that inhibition of pAkt and activation of p53 pathway are the main molecular events involved in inhibitory effects of TSA.
11 schema:genre article
12 schema:inLanguage en
13 schema:isAccessibleForFree true
14 schema:isPartOf Nc38bcc2c94e243be93585cc157f916d5
15 Ne2ed5d8fc83143a08034838e9390c4bb
16 sg:journal.1030596
17 schema:keywords CCK-8 assay
18 DLBCL cell growth
19 DLBCL cell lines
20 DoHH2 cells
21 H3
22 HDAC inhibitor TSA
23 HDAC inhibitors
24 HDAC profiling
25 HDAC1-6 expression levels
26 HDACs
27 TSA
28 TSA treatment
29 Western blot analysis
30 acetylation
31 activation
32 altered expression
33 analysis
34 anti-proliferative effects
35 apoptosis
36 arrest
37 assays
38 behavior
39 biological behavior
40 blot analysis
41 cell cycle arrest
42 cell cycle distribution
43 cell growth
44 cell lines
45 cell lymphoma
46 cell lymphoma cell lines
47 cells
48 control
49 cycle arrest
50 cycle distribution
51 cytometry
52 data
53 date
54 deacetylase inhibitors
55 dephosphorylation
56 dephosphorylation of pAkt
57 diffuse
58 distribution
59 downstream effectors
60 effect
61 effectors
62 enhanced cell cycle arrest
63 epigenetic control
64 epigenetic targets
65 events
66 expression
67 expression levels
68 flow cytometry
69 further understanding
70 great importance
71 growth
72 high expression
73 high sensitivity
74 histone H3
75 histone deacetylase inhibitors
76 importance
77 inhibition
78 inhibition of pAKT
79 inhibitor TSA
80 inhibitors
81 inhibitory effect
82 insights
83 isoforms
84 levels
85 lines
86 lymphoma
87 lymphoma cell lines
88 main downstream effectors
89 main molecular events
90 mechanism
91 molecular analysis
92 molecular events
93 molecular mechanisms
94 p53
95 p53 pathway
96 pAkt
97 pathway
98 potential epigenetic targets
99 profiling
100 promising therapy
101 protein
102 relevant proteins
103 results
104 sensitivity
105 target
106 therapy
107 treatment
108 trichostatin A
109 tubulin
110 understanding
111 upregulated acetylation
112 schema:name The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms
113 schema:pagination 57-57
114 schema:productId Naa28b7b9fb4d4207ab250bca0155201e
115 Ne4b205d3006c427287d6ca9ed1fe287d
116 Nf0a070c1d5b745c996a86cd30435fc1d
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036997840
118 https://doi.org/10.1186/1475-2867-13-57
119 schema:sdDatePublished 2022-01-01T18:30
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher Nf16415f3a5864515b71168821581a3a9
122 schema:url https://doi.org/10.1186/1475-2867-13-57
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N4ec174b8427d4f6ba35cf390f7b1cd13 rdf:first N9668ea64e6e6422493900d3d7f1c0f51
127 rdf:rest N928970fb574345488209a907c7bb57a6
128 N769f650ab78b426b93f99f5352e6edf1 rdf:first sg:person.01010610662.09
129 rdf:rest rdf:nil
130 N7e178440112842239624f47b227a5df3 rdf:first sg:person.01257402372.20
131 rdf:rest Nf7bf135bfa7942108e4fbe0f2d477e3b
132 N928970fb574345488209a907c7bb57a6 rdf:first sg:person.01103220634.32
133 rdf:rest N769f650ab78b426b93f99f5352e6edf1
134 N9668ea64e6e6422493900d3d7f1c0f51 schema:affiliation grid-institutes:grid.452404.3
135 schema:familyName Zhang
136 schema:givenName Ping
137 rdf:type schema:Person
138 Naa28b7b9fb4d4207ab250bca0155201e schema:name doi
139 schema:value 10.1186/1475-2867-13-57
140 rdf:type schema:PropertyValue
141 Nb69f5e1f1be542768233eed4e9f105ad rdf:first sg:person.0667777664.13
142 rdf:rest Ne86c410aea044ad99cf07bad5d3566bc
143 Nc38bcc2c94e243be93585cc157f916d5 schema:volumeNumber 13
144 rdf:type schema:PublicationVolume
145 Ne2ed5d8fc83143a08034838e9390c4bb schema:issueNumber 1
146 rdf:type schema:PublicationIssue
147 Ne4b205d3006c427287d6ca9ed1fe287d schema:name pubmed_id
148 schema:value 23758695
149 rdf:type schema:PropertyValue
150 Ne6672b1e210844cd96857aad5c175f65 rdf:first sg:person.0674362262.07
151 rdf:rest N7e178440112842239624f47b227a5df3
152 Ne86c410aea044ad99cf07bad5d3566bc rdf:first sg:person.01336110623.41
153 rdf:rest Ne6672b1e210844cd96857aad5c175f65
154 Nf0a070c1d5b745c996a86cd30435fc1d schema:name dimensions_id
155 schema:value pub.1036997840
156 rdf:type schema:PropertyValue
157 Nf16415f3a5864515b71168821581a3a9 schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 Nf7bf135bfa7942108e4fbe0f2d477e3b rdf:first sg:person.01117741622.59
160 rdf:rest N4ec174b8427d4f6ba35cf390f7b1cd13
161 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
162 schema:name Medical and Health Sciences
163 rdf:type schema:DefinedTerm
164 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
165 schema:name Oncology and Carcinogenesis
166 rdf:type schema:DefinedTerm
167 sg:journal.1030596 schema:issn 1475-2867
168 schema:name Cancer Cell International
169 schema:publisher Springer Nature
170 rdf:type schema:Periodical
171 sg:person.01010610662.09 schema:affiliation grid-institutes:grid.8547.e
172 schema:familyName Zhou
173 schema:givenName Xiaoyan
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010610662.09
175 rdf:type schema:Person
176 sg:person.01103220634.32 schema:affiliation grid-institutes:grid.8547.e
177 schema:familyName Bi
178 schema:givenName Rui
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103220634.32
180 rdf:type schema:Person
181 sg:person.01117741622.59 schema:affiliation grid-institutes:grid.452404.3
182 schema:familyName Chi
183 schema:givenName Yayun
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117741622.59
185 rdf:type schema:Person
186 sg:person.01257402372.20 schema:affiliation grid-institutes:grid.8547.e
187 schema:familyName Wei
188 schema:givenName Ping
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257402372.20
190 rdf:type schema:Person
191 sg:person.01336110623.41 schema:affiliation grid-institutes:grid.8547.e
192 schema:familyName Cui
193 schema:givenName Wenli
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336110623.41
195 rdf:type schema:Person
196 sg:person.0667777664.13 schema:affiliation grid-institutes:grid.8547.e
197 schema:familyName Cai
198 schema:givenName Ying
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667777664.13
200 rdf:type schema:Person
201 sg:person.0674362262.07 schema:affiliation grid-institutes:grid.8547.e
202 schema:familyName Chen
203 schema:givenName Weixiang
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674362262.07
205 rdf:type schema:Person
206 sg:pub.10.1007/s10637-010-9591-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051959658
207 https://doi.org/10.1007/s10637-010-9591-3
208 rdf:type schema:CreativeWork
209 sg:pub.10.1038/onc.2012.81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012645003
210 https://doi.org/10.1038/onc.2012.81
211 rdf:type schema:CreativeWork
212 sg:pub.10.1038/sj.bjc.6600905 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051493456
213 https://doi.org/10.1038/sj.bjc.6600905
214 rdf:type schema:CreativeWork
215 sg:pub.10.1038/sj.onc.1210614 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051261327
216 https://doi.org/10.1038/sj.onc.1210614
217 rdf:type schema:CreativeWork
218 grid-institutes:grid.452404.3 schema:alternateName Cancer Research Institute, Fudan University Shanghai Cancer Center, Shanghai, PR China
219 schema:name Cancer Research Institute, Fudan University Shanghai Cancer Center, Shanghai, PR China
220 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China
221 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China
222 Institute of Pathology, Fudan University, Shanghai, PR China
223 rdf:type schema:Organization
224 grid-institutes:grid.8547.e schema:alternateName Institute of Pathology, Fudan University, Shanghai, PR China
225 schema:name Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China
226 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China
227 Institute of Pathology, Fudan University, Shanghai, PR China
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...